Topics

Nimble Therapeutics spins out of Roche to focus on peptide R&D

07:51 EDT 1 May 2019 | pharmaphorum

US biotech Nimble Therapeutics has announced it is operating as a standalone business after spinning out from Roche, focusing on drug R&D based around peptides. Acquired by Roche Diagnostics in 2007, the pharma giant had considered the unit su...

Original Article: Nimble Therapeutics spins out of Roche to focus on peptide R&D

NEXT ARTICLE

More From BioPortfolio on "Nimble Therapeutics spins out of Roche to focus on peptide R&D"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...